comparemela.com

Latest Breaking News On - Kate haranis - Page 6 : comparemela.com

Will Johnson & Johnson buy Boston Scientific?

A Needham & Co. analyst upgraded his rating of Boston Scientific shares to Buy, partly because he thinks it's an acquisition target for J&J.

United statesMike matsonJoe wolkMassdevice medtechKate haranisNeedham coBoston scientific

Boston Scientific to Participate in Bank of America Global Healthcare Conference

/PRNewswire/ Boston Scientific Corporation (NYSE: BSX) will participate in Bank of America s Global Healthcare Conference on Thursday, May 12. Dan Brennan,.

United statesLauren tenglerDan brennanKate haranisBoston scientific corporationPrnewswire boston scientific corporationBoston scientificScientific corporationGlobal healthcare conferenceInvestor relations

BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR FIRST QUARTER 2022

MARLBOROUGH, Mass., April 27, 2022 /PRNewswire/ Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.026 billion during the firs.

United statesLauren tenglerMike mahoneyKate haranisBoston scientific corporationBaylis medical company incNational cardiovascular dataEuropean heart rhythm associationDrug administrationBoston scientificPelvic healthSpecialty pharmaceuticalsExchange commissionPrnewswire boston scientific corporationSecurities exchangeNational medical products administration

BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR FIRST QUARTER 2022

/PRNewswire/ Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.026 billion during the first quarter of 2022, growing 10.0 percent on a.

United statesLauren tenglerMike mahoneyKate haranisBoston scientific corporationBaylis medical company incNational cardiovascular dataEuropean heart rhythm associationDrug administrationBoston scientificPelvic healthSpecialty pharmaceuticalsExchange commissionPrnewswire boston scientific corporationSecurities exchangeNational medical products administration

BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR FIRST QUARTER 2022

/PRNewswire/ Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.026 billion during the first quarter of 2022, growing 10.0 percent on a.

United statesLauren tenglerMike mahoneyKate haranisBoston scientific corporationBaylis medical company incNational cardiovascular dataEuropean heart rhythm associationDrug administrationBoston scientificPelvic healthSpecialty pharmaceuticalsExchange commissionPrnewswire boston scientific corporationSecurities exchangeNational medical products administration

vimarsana © 2020. All Rights Reserved.